Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439738 · ClinicalTrials.gov registry record · Phase 4
Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 412
- Enrollment target
NCT00439738 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 412 participants.
The verdict
NCT00439738, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 412 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure \[MSSBP\] \>150 mmHg) patients.
Interventions
- DRUG Valsartan/HCTZ
- DRUG HCTZ + Amlodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2006-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00439738
The ClinicalTrials.gov registry entry for NCT00439738 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 412 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Valsartan/HCTZ is the first listed.
NCT00439738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00439738 about?
NCT00439738 is a clinical study titled "Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults". The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure \[MSSBP\] \>150 mmHg) patients.
What is the current status of trial NCT00439738?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 412 participants. The study started on 2006-12.
What interventions are being tested in trial NCT00439738?
The interventions under investigation include: Valsartan/HCTZ (DRUG), HCTZ + Amlodipine (DRUG).
Who is sponsoring clinical trial NCT00439738?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.